目的研究达沙替尼在慢性髓性白血病(CML)伊马替尼耐药或不耐受患者中的应用价值。方法根据用药不同将90例CML伊马替尼耐药或不耐受患者随机分为对照组(尼洛替尼治疗)和观察组(达沙替尼治疗),各45例。观察两组完全细胞遗传学(CCy R)、完全血液学(CHR)、主要生物分子学(MMR)/完全分子生物学(CMR)缓解率及不良反应发生率。结果与对照组比较,观察组慢性期患者CCy R缓解率及加速期患者CHR、MMR/CMR缓解率均更高,加速期死亡率及进展率更低,治疗期间不良反应更少,差异均有统计学意义(P<0.05)。结论达沙替尼治疗慢性髓性白血病伊马替尼耐药或不耐受患者的临床疗效优,患者更耐受,值得推广。 Objective To investigate the clinical value of dasatinib in drug resistant or intolerant patients with chronic myelogenous leukemia (CML). Methods Ninety patients with resistant or intolerant CML patients were randomly divided into control group (nilotinib group) and observation group (dasatinib group), 45 cases in each group. The complete cytogenetics (CCy R), complete hematology (CHR), major biomolecular (MMR) / complete molecular biology (CMR) remission rates and incidence of adverse reactions were observed in the two groups. Results Compared with the control group, the response rates of CCy R and CHR and MMR / CMR in patients with chronic phase in the observation group were higher than those in the control group, and the mortality and progression rate were lower in the accelerated phase and less adverse reactions during the treatment period Statistical significance (P <0.05). Conclusion Dasatinib in patients with chronic myelogenous leukemia imatinib resistant or intolerant patients with excellent clinical efficacy, patients are more tolerable, it is worth promoting.